BRPI0908569A2 - estimuladores de secreção de insulina derivados de piridopirazinonas, métodos para obtê-los e uso dos mesmos para o tratamento de diabetes - Google Patents

estimuladores de secreção de insulina derivados de piridopirazinonas, métodos para obtê-los e uso dos mesmos para o tratamento de diabetes

Info

Publication number
BRPI0908569A2
BRPI0908569A2 BRPI0908569A BRPI0908569A BRPI0908569A2 BR PI0908569 A2 BRPI0908569 A2 BR PI0908569A2 BR PI0908569 A BRPI0908569 A BR PI0908569A BR PI0908569 A BRPI0908569 A BR PI0908569A BR PI0908569 A2 BRPI0908569 A2 BR PI0908569A2
Authority
BR
Brazil
Prior art keywords
pyridopyrazinone
diabetes
obtaining
treatment
methods
Prior art date
Application number
BRPI0908569A
Other languages
English (en)
Inventor
Christine Charon
Eric Valeur
Gérard Botton
Micheline Kergoat
Samer Elbawab
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BRPI0908569A2 publication Critical patent/BRPI0908569A2/pt
Publication of BRPI0908569B1 publication Critical patent/BRPI0908569B1/pt
Publication of BRPI0908569B8 publication Critical patent/BRPI0908569B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
BRPI0908569A 2008-03-05 2009-02-27 estimuladores de secreção de insulina derivados de piridopirazinonas, seu uso, e composição farmacêutica BRPI0908569B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08004052.0 2008-03-05
EP08004052 2008-03-05
PCT/EP2009/001428 WO2009109341A1 (en) 2008-03-05 2009-02-27 Pyridopyrazinones derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes

Publications (3)

Publication Number Publication Date
BRPI0908569A2 true BRPI0908569A2 (pt) 2015-09-22
BRPI0908569B1 BRPI0908569B1 (pt) 2020-02-11
BRPI0908569B8 BRPI0908569B8 (pt) 2021-05-25

Family

ID=40533371

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0908569A BRPI0908569B8 (pt) 2008-03-05 2009-02-27 estimuladores de secreção de insulina derivados de piridopirazinonas, seu uso, e composição farmacêutica

Country Status (18)

Country Link
US (3) US8178556B2 (pt)
EP (1) EP2247292B1 (pt)
JP (2) JP5735806B2 (pt)
KR (1) KR101589628B1 (pt)
CN (1) CN101951909B (pt)
AR (1) AR070796A1 (pt)
AU (1) AU2009221213B2 (pt)
BR (1) BRPI0908569B8 (pt)
CA (1) CA2718402C (pt)
DK (1) DK2247292T3 (pt)
EA (1) EA020372B1 (pt)
ES (1) ES2632964T3 (pt)
HU (1) HUE033849T2 (pt)
IL (1) IL207722A (pt)
MX (1) MX2010009577A (pt)
PT (1) PT2247292T (pt)
WO (1) WO2009109341A1 (pt)
ZA (1) ZA201007061B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0008864A1 (en) 1978-08-15 1980-03-19 FISONS plc Pyridopyrazine and quinoxaline derivatives, processes for their preparation, and pharmaceutical compositions containing them
GB9413975D0 (en) 1994-07-11 1994-08-31 Fujisawa Pharmaceutical Co New heterobicyclic derivatives
JPH05155884A (ja) 1991-12-10 1993-06-22 Kyowa Hakko Kogyo Co Ltd 縮合ピラジン誘導体
GB9526558D0 (en) * 1995-12-27 1996-02-28 Fujisawa Pharmaceutical Co Heterobicyclic derivatives
SE9800836D0 (sv) 1998-03-13 1998-03-13 Astra Ab New Compounds
US6200976B1 (en) * 1998-04-17 2001-03-13 Boehringer Ingelheim Pharma Kg Antithrombotic quinoxazolines
DE19816983A1 (de) * 1998-04-17 1999-10-21 Boehringer Ingelheim Pharma Bicyclen, deren Herstellung und deren Verwendung als Arzneimittel
JP2000154139A (ja) * 1998-09-16 2000-06-06 Kyowa Hakko Kogyo Co Ltd 縮環ピラジン誘導体
WO2002076954A1 (en) * 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
US7067658B2 (en) 2002-09-30 2006-06-27 Bristol-Myers Squibb Company Pyridino and pyrimidino pyrazinones
WO2005021547A2 (en) * 2003-08-28 2005-03-10 Pharmaxis Pty Ltd. Heterocyclic cannabinoid cb2 receptor antagonists
ATE367161T1 (de) 2004-01-06 2007-08-15 Janssen Pharmaceutica Nv (3-oxo-3,4-dihydro-chinoxalin-2-yl-amino)- benzamid-derivate und verwandte verbindungen als glykogen-phosphorylase-hemmer zur behandlung von diabetes und adipositas
CA2603830A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Co Llc PYRIDINE [2,3-B] PYRAZINONES
WO2006126082A2 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
WO2006126083A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors
WO2007020521A1 (en) * 2005-08-16 2007-02-22 Pharmacia & Upjohn Company Llc Pyridoyrazinones as pde-5 inhibitors
EP2004193A2 (en) * 2006-03-13 2008-12-24 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
WO2007109868A2 (en) * 2006-03-29 2007-10-04 Ivelin Terziev Fishing float
CA2649775C (en) 2006-04-21 2011-05-31 Pfizer Products Inc. Pyridine[3,4-b]pyrazinones
US7893066B2 (en) 2006-10-05 2011-02-22 Gilead Palo Alto, Inc. Pyridol[2,3-B]pyrazinones for use as stearoyl CoA desaturase inhibitors
RU2009112397A (ru) * 2006-10-05 2010-10-10 Си Ви ТЕРАПЬЮТИКС, ИНК (US) Бициклические азотсодержащие гетероциклические соединения для применения в качестве ингибиторов стеароил соа десатуразы
NZ582940A (en) * 2007-08-31 2013-01-25 Purdue Pharma Lp Substituted-quinoxaline-type piperidine compounds and the uses thereof

Also Published As

Publication number Publication date
US8178556B2 (en) 2012-05-15
ZA201007061B (en) 2011-06-29
JP5735806B2 (ja) 2015-06-17
DK2247292T3 (en) 2017-06-06
AR070796A1 (es) 2010-05-05
US20120122876A1 (en) 2012-05-17
EA020372B1 (ru) 2014-10-30
US8642617B2 (en) 2014-02-04
KR20100124803A (ko) 2010-11-29
CA2718402C (en) 2017-08-22
CN101951909A (zh) 2011-01-19
AU2009221213B2 (en) 2014-02-27
ES2632964T3 (es) 2017-09-18
JP2011514896A (ja) 2011-05-12
JP2015034184A (ja) 2015-02-19
US20110009417A1 (en) 2011-01-13
CN101951909B (zh) 2013-05-15
IL207722A0 (en) 2010-12-30
JP6031079B2 (ja) 2016-11-24
EA201001405A1 (ru) 2011-04-29
AU2009221213A1 (en) 2009-09-11
BRPI0908569B8 (pt) 2021-05-25
EP2247292B1 (en) 2017-04-12
MX2010009577A (es) 2010-09-24
HUE033849T2 (en) 2018-01-29
PT2247292T (pt) 2017-07-17
KR101589628B1 (ko) 2016-01-28
IL207722A (en) 2015-09-24
US8609689B2 (en) 2013-12-17
EP2247292A1 (en) 2010-11-10
CA2718402A1 (en) 2009-09-11
WO2009109341A1 (en) 2009-09-11
US20130023537A1 (en) 2013-01-24
BRPI0908569B1 (pt) 2020-02-11

Similar Documents

Publication Publication Date Title
HUE038279T2 (hu) Klotho-béta-agonista antitest cukorbetegség vagy inzulinrezisztencia kezelésében történõ alkalmazásra
BRPI0811635A2 (pt) Compostos de arilazol-2-il cianoetilamino, métodos para fazê-los e métodos para o uso dos mesmos
BRPI0921389A2 (pt) seringa de um só uso, de inutilização automática
BRPI0919288A2 (pt) teriapia de combinação para tratamento de diabetes e condições relacionadas.
BRPI0819188A2 (pt) Uso de melanocortinas para tratar sensibilidade à insulina.
BRPI0907453A2 (pt) Compostos, uso e preparação dos mesmos
BRPI0816318A2 (pt) Dispositivo de liberação transdérmica, e, método para preparar o mesmo
CL2015001207A1 (es) Composición para prevenir o tratar diabetes, diabesidad o complicaciones diabéticas, que comprende un análogo de oxintomodulina; y uso de la composición.
BR112012022879A2 (pt) composto, composição farmacêutica, uso do composto e método de tratamento
BR112012003661A2 (pt) "compostos de biarila e métodos de uso dos mesmos."
BRPI1013992A2 (pt) composições e métodos para o tratamento de resistência à insulina e diabetes melito
BRPI0813237A2 (pt) Composto, método para preparar o composto, composição, medicamento, e, uso do composto.
BR112012022878A2 (pt) composto, composição farmacêutica, uso do compostos e método de tratamento
BRPI0917535A2 (pt) uso de insulina de ação ultra rápida
LT3124043T (lt) Nauja imunoterapija prieš tam tikrus navikus, įskaitant neuronų ir galvos smegenų navikus
BRPI1010304A2 (pt) dispositivo de espectroscopia óptica para detecção de glicose no sangue não invasiva e método de uso associado.
BRPI0921546A2 (pt) Compostos de arilazol-2-il cianoetilamina enriquecidos enantiomericamente, método para fabricação e método de uso dos mesmos
BRPI0921997A2 (pt) dispositivo para medição do componente de sangue.
BRPI0913739A2 (pt) Composição líquida, método, e, uso de composição
BRPI1006145A2 (pt) "composição e método para tratamento de diabetes".
BRPI0922233A2 (pt) compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas.
PL3133396T3 (pl) Sposób leczenia z zastosowaniem leków wychwytujących amoniak
BRPI0908406A2 (pt) Derivados de quinoxalinona como estimulantes da secreção de insulina, métodos para obtenção dos mesmos e uso dos mesmos para tratamento do diabetes
BRPI0919794A2 (pt) dispositivo para uso intracorpóreo, e, composto
BRPI1006996A2 (pt) composição, método e uso

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/02/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/02/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2822 DE 04-02-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.